Denali Therapeutics マネジメント
マネジメント 基準チェック /44
Denali Therapeuticsの CEO はRyan Wattsで、 Aug2015年に任命され、 の在任期間は 9.25年です。 の年間総報酬は$ 7.88Mで、 8.5%給与と91.5%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の1.56%を直接所有しており、その価値は$ 54.91M 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と8.1年です。
主要情報
Ryan Watts
最高経営責任者
US$7.9m
報酬総額
| CEO給与比率 | 8.5% |
| CEO在任期間 | 9.3yrs |
| CEOの所有権 | 1.6% |
| 経営陣の平均在職期間 | 5.8yrs |
| 取締役会の平均在任期間 | 8.1yrs |
経営陣の近況
Recent updates
Denali Therapeutics: A Promising Biotech With Revolutionary BBB-Crossing Technology
Aug 20Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Jul 26
Revenues Not Telling The Story For Denali Therapeutics Inc. (NASDAQ:DNLI) After Shares Rise 25%
May 23Denali Therapeutics: MPS Treatment Program Continues With End Of 2024 Data
May 13An Intrinsic Calculation For Denali Therapeutics Inc. (NASDAQ:DNLI) Suggests It's 44% Undervalued
Apr 17Denali Therapeutics Inc.'s (NASDAQ:DNLI) Price Is Right But Growth Is Lacking After Shares Rocket 25%
Mar 21Denali: Leveraging Transport Vehicle Technology For Neurological Gains
Mar 07Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Feb 21Improved Revenues Required Before Denali Therapeutics Inc. (NASDAQ:DNLI) Shares Find Their Feet
Jan 26We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Nov 20Investor Optimism Abounds Denali Therapeutics Inc. (NASDAQ:DNLI) But Growth Is Lacking
Oct 09Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Aug 22Denali Therapeutics Inc.'s (NASDAQ:DNLI) Intrinsic Value Is Potentially 69% Above Its Share Price
May 02Analysts Are More Bearish On Denali Therapeutics Inc. (NASDAQ:DNLI) Than They Used To Be
Mar 04Here's Why We're Not Too Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Situation
Feb 06These Analysts Think Denali Therapeutics Inc.'s (NASDAQ:DNLI) Sales Are Under Threat
Nov 09Denali Therapeutics proposes $250M stock offering; shares down 6% post market
Oct 18Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth
Oct 12Biogen, Denali begin dosing in late-stage trial of Parkinson's candidate BIIB122
Oct 10We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate
Jun 08CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$427m |
| Jun 30 2024 | n/a | n/a | -US$420m |
| Mar 31 2024 | n/a | n/a | -US$137m |
| Dec 31 2023 | US$8m | US$670k | -US$145m |
| Sep 30 2023 | n/a | n/a | -US$124m |
| Jun 30 2023 | n/a | n/a | -US$128m |
| Mar 31 2023 | n/a | n/a | -US$371m |
| Dec 31 2022 | US$9m | US$645k | -US$326m |
| Sep 30 2022 | n/a | n/a | -US$303m |
| Jun 30 2022 | n/a | n/a | -US$284m |
| Mar 31 2022 | n/a | n/a | -US$286m |
| Dec 31 2021 | US$13m | US$610k | -US$291m |
| Sep 30 2021 | n/a | n/a | US$30m |
| Jun 30 2021 | n/a | n/a | US$56m |
| Mar 31 2021 | n/a | n/a | US$58m |
| Dec 31 2020 | US$9m | US$589k | US$71m |
| Sep 30 2020 | n/a | n/a | -US$228m |
| Jun 30 2020 | n/a | n/a | -US$216m |
| Mar 31 2020 | n/a | n/a | -US$215m |
| Dec 31 2019 | US$5m | US$567k | -US$198m |
| Sep 30 2019 | n/a | n/a | -US$66m |
| Jun 30 2019 | n/a | n/a | -US$55m |
| Mar 31 2019 | n/a | n/a | -US$52m |
| Dec 31 2018 | US$6m | US$545k | -US$36m |
| Sep 30 2018 | n/a | n/a | -US$137m |
| Jun 30 2018 | n/a | n/a | -US$123m |
| Mar 31 2018 | n/a | n/a | -US$91m |
| Dec 31 2017 | US$1m | US$481k | -US$88m |
報酬と市場: Ryanの 総報酬 ($USD 7.88M ) は、 US市場 ($USD 6.54M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Ryanの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Ryan Watts (48 yo)
9.3yrs
在職期間
US$7,879,267
報酬
Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 9.3yrs | US$7.88m | 1.56% $ 54.9m | |
| Co-Founder | 9.7yrs | US$4.17m | 0.41% $ 14.3m | |
| Co-Founder & Independent Director | no data | US$431.93k | 1.47% $ 51.7m | |
| Chief Medical Officer & Head of Development | 9.4yrs | US$4.17m | 0.14% $ 5.1m | |
| Senior Vice President of Corporate Finance | no data | データなし | データなし | |
| Chief Technical and Manufacturing Officer | 6.3yrs | データなし | データなし | |
| Chief Scientific Officer | 4.3yrs | データなし | データなし | |
| Vice President of Investor Relations | 4.8yrs | データなし | データなし | |
| General Counsel | 5.8yrs | データなし | データなし | |
| Vice President of Corporate Development | 1.8yrs | データなし | データなし | |
| Chief People Officer | no data | データなし | データなし | |
| Chief Commercial Officer | 3.2yrs | データなし | データなし |
5.8yrs
平均在職期間
51yo
平均年齢
経験豊富な経営陣: DNLIの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Co-Founder | 9.7yrs | US$7.88m | 1.56% $ 54.9m | |
| Co-Founder & Independent Director | 9.7yrs | US$431.93k | 1.47% $ 51.7m | |
| Independent Chairperson | 9.6yrs | US$459.43k | 0.073% $ 2.6m | |
| Independent Director | 9.6yrs | US$444.43k | 0.24% $ 8.3m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 9.6yrs | US$439.43k | 0.042% $ 1.5m | |
| Member of Scientific Advisory Board | 4yrs | データなし | データなし | |
| Independent Director | 6.7yrs | US$439.43k | 0.011% $ 380.5k | |
| Independent Director | 6yrs | US$429.43k | 0.0098% $ 344.9k | |
| Director | 2.5yrs | US$419.43k | 0.57% $ 20.3m | |
| Member of Scientific Advisory Board | no data | データなし | データなし | |
| Member of Scientific Advisory Board | 3.8yrs | データなし | データなし |
8.1yrs
平均在職期間
64yo
平均年齢
経験豊富なボード: DNLIの 取締役会 は 経験豊富 であると考えられます ( 8.1年の平均在任期間)。